No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 3 of the 30 quarters in the window, leaving 27 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 3.9x · 10Y median 4.2x · 49th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:37.055Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T13:21:37.055Z. Latest historical point 2021-11-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:21:37.055Z. Latest historical point 2025-05-15.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:21:37.055Z. Latest historical point 2021-11-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Precision BioSciences, Inc. (DTIL) stock was $6.31 as of Oct 5, 2026, 4:00 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months +15.9% · 3-year avg -12.5%/yr · 5-year avg -54.8%/yr
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies.
Biotechnology · Durham, NC
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
-0.85
Revenue Est.
$1.38M
Last Quarter Results
EPS
$-1.26
vs Estimate
$-0.69
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DTIL | $174.17M | $6.31 | +0.00% | +15.91% | -54.84% | N/A | N/A |
| 2CHRS | $173.04M | $1.12 | -3.45% | -31.58% | -41.38% | -26.92% | vs DTIL |
| 3CMPX | $172.99M | $0.96 | +12.13% | -73.87% | -22.79% | N/A | vs DTIL |
| 4CUE | $176.96M | $24.36 | -4.73% | +11.33% | -42.42% | N/A | vs DTIL |
| 5CNTN | $179.70M | $2.33 | +3.56% | -19.85% | N/A | N/A | vs DTIL |
| 6DERM | $184.12M | $6.69 | +1.21% | -8.69% | N/A | N/A | vs DTIL |
forward FY estimate
N/A
$0.00
vs Estimate
$740000.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$6.31
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.99 | $-0.85 | $-0.71 | 2 |
| Quarter ending Dec 2026 | $-0.85 | $-0.83 | $-0.81 | 2 |
| Quarter ending Mar 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Quarter ending Jun 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.71 | $-3.59 | $-3.47 | 3 |
| FY 2027 | $-3.31 | $-2.84 | $-2.37 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.38M | $1.38M | $1.38M | 2 |
| Quarter ending Dec 2026 | $1.25M | $1.25M | $1.25M | 4 |
| Quarter ending Mar 2027 | $2.50M | $2.50M | $2.50M | 2 |
| Quarter ending Jun 2027 | $2.50M | $2.50M | $2.50M | 2 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $13.31M | $13.43M | $13.56M | 3 |
| FY 2027 | $7.44M | $8.88M | $10.43M | 3 |
